Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth

BACKGROUND: Increased exposure to multitargeted kinase inhibitor sunitinib is associated with improved outcome, emphasizing the importance of maintaining adequate dosing and drug levels. The currently approved schedule (50 mg daily, four weeks on, two weeks off) precludes further dose-intensificatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Rovithi, Maria, de Haas, Richard R., Honeywell, Richard J., Poel, Dennis, Peters, Godefridus J., Griffioen, Arjan W., Verheul, Henk M. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5013589/
https://www.ncbi.nlm.nih.gov/pubmed/27604186
http://dx.doi.org/10.1186/s13046-016-0411-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5013589/
https://www.ncbi.nlm.nih.gov/pubmed/27604186
http://dx.doi.org/10.1186/s13046-016-0411-2

Ejemplares similares